Show simple item record

dc.contributor.authorSánchez Avila, Ronald M.
dc.contributor.authorMerayo Lloves, Jesús
dc.contributor.authorRiestra, Ana C.
dc.contributor.authorBerisa, Silvia
dc.contributor.authorLisa Fernández, Carlos
dc.contributor.authorAlfonso Sánchez, José
dc.contributor.authorMuruzabal, Francisco J.
dc.contributor.authorOrive Arroyo, Gorka
dc.contributor.authorAnitua Aldekoa, Eduardo
dc.date.accessioned2018-12-20T11:58:14Z
dc.date.available2018-12-20T11:58:14Z
dc.date.issued2018-04
dc.identifier.citationMedicine 97 : (2018) // Article ID e0242es_ES
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.urihttp://hdl.handle.net/10810/30470
dc.description.abstractTo evaluate the safety and efficacy of the surgical use of plasma rich in growth factors fibrin membrane (mPRGF) in different ocular surface pathologies.Fifteen patients with different corneal and conjunctival diseases were included in the study. Patients were grouped according to the use of mPRGF as graft (corneal and/or conjunctival) or dressing; they were also grouped according to the surgical subgroup of intervention (persistent corneal ulcer [PCU], keratoplasty, superficial keratectomy, corneal perforation, and pterygium). Best corrected visual acuity, intraocular pressure (IOP), inflammation control time (ICT), mPRGF AT (PRGF membrane absorption time), and the healing time of the epithelial defect (HTED) were evaluated throughout the clinical follow-up time. Safety assessment was also performed reporting all adverse events.mPRGF showed a total closure of the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients (13.3%). The mean follow-up time was 11.14.2 (4.8-22.8) months, the mean ICT was 2.5 +/- 1.1 (1.0-4.0) months, the mean mPRGF AT was 12.4 +/- 2.0 (10.0-16.0) days, and for the global HTED the mean was 2.9 +/- 1.2 (1-4.8) months. Results showed an improvement in BCVA in all patients, with an overall improvement of 2.9 in Vision Lines. The BCVA significantly improved (P<.05) in the groups of corneal graft and dressing. In the PCU subgroup (6 patients), the healing time of epithelial defect was significantly reduced (P<.05) in patients treated only with the mPRGF in comparison to those which mPRGF therapy was associated to the amniotic membrane. The IOP remained stable (P>.05) throughout the clinical follow-up time. No adverse events were reported after mPRGF use.The mPRGF is effective and safe as coadjuvant treatment in surgeries related with ocular surface disorders, being an alternative to the use of amniotic membrane. The mPRGF accelerates tissue regeneration after ocular surface surgery thus minimizing inflammation and fibrosis.es_ES
dc.description.sponsorshipThis study received funding from the Ministry of Economy and Competitiveness of the Spanish Government, within the project denominated SURFEYE (reference RTC-2014-2375-1).es_ES
dc.language.isoenges_ES
dc.publisherLippincott Williams & Wilkinses_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/RTC-2014-2375-1es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcorneal and ocular surface diseaseses_ES
dc.subjectfibrin membranees_ES
dc.subjectplasma rich in growth factorses_ES
dc.subjectplatelet-rich plasmaes_ES
dc.subjectPRGFes_ES
dc.subjectPRPes_ES
dc.subjectepithelial progenitor cellses_ES
dc.subjectamniotic membranees_ES
dc.subjectautologous serumes_ES
dc.subjectrelease kineticses_ES
dc.subjectcorneal ulcerses_ES
dc.subjectstem-celles_ES
dc.subjecttransplantationes_ES
dc.subjectreconstructiones_ES
dc.subjectdeficiencyes_ES
dc.subjectmanagementes_ES
dc.titlePlasma Rich in Growth Factors Membrane as Coadjuvant Treatment in the Surgery of Ocular Surface Disorderses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderCopyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://journals.lww.com/md-journal/fulltext/2018/04270/Plasma_rich_in_growth_factors_membrane_as.3.aspxes_ES
dc.identifier.doi10.1097/MD.0000000000010242
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.